Market Herald logo

Subscribe

Be the first with the news that moves the market
  • LexaGene Holdings Inc. (LXG) has announced the release of its second-generation MiQLab Bacterial and AMR Panel for veterinary practices
  • Version two of the test can screen for 10 pathogens and 35 genes and variants, a significant increase compared the first version
  • The MiQLab System provides rapid testing for pathogens and markers of antibiotic resistance so that veterinarians can make fast, evidence-based treatment decisions
  • LexaGene Holdings Inc. is a molecular diagnostics company
  • LexaGene Holdings Inc. (LXG) is down 7.25 per cent, trading at $0.64 per share

LexaGene Holdings Inc. (LXG) has announced the release of its second-generation MiQLab Bacterial and AMR Panel for veterinary practices.

The first Bacterial and AMR (Antibiotic/Antimicrobial Resistance) test was able to screen patient samples for seven different pathogens and 13 different antimicrobial resistance factors.

Version two, which was launched today, can screen for 10 pathogens and 35 genes and variants to determine antimicrobial drug resistance.

Dr. Jack Regan, founder and CEO of LexaGene, listed three reasons that the new test will drive LexaGene’s growth:

“First and foremost, veterinarians using this technology will be able to provide better informed and more timely care for pets.

“Second, we expect veterinarians to run more tests per week using MiQLab rather than sending samples to a reference lab for culture, as MiQLab testing provides enhanced customer peace-of-mind, with critical diagnostic information available within two hours versus three to five days.

“And, as the technology can be now used across many more medical applications, we expect this new release will increase the number of tests run by current LexaGene veterinary customers and serve as a potential profit center for their practices.”

LexaGene’s MiQLab System provides rapid testing for pathogens and markers of antibiotic resistance so that veterinarians can make fast, evidence-based treatment decisions.

LexaGene Holdings Inc. is a molecular diagnostics company that develops systems for on-site rapid testing in veterinary diagnostics, food safety, clinical research, agricultural testing, and biodefense.

LexaGene Holdings Inc. (LXG) is down 7.25 per cent, trading at $0.64 per share as of 12:23 pm ET.

More From The Market Herald

" BlackBerry (TSX:BB) launches Google Chrome Enterprise Management

BlackBerry (BB) has launched Chrome Enterprise Management under its UEM service.
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
FansUnite - CEO, Scott Burton.

" FansUnite (CSE:FANS) reports Q1 2022 financial results

FansUnite (FANS) has filed its interim financial statements for the three months ended March 31, 2022.